Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Pediatr Infect Dis J. 2012 Jun;31(6):583-91. doi: 10.1097/INF.0b013e31824da0f5.
Gut microbial translocation (MT) is considered a major cause of immune activation (IA) and failure of immune reconstitution in HIV infection. This study investigated the relationship of virus replication, IA, CD4 counts and MT in HIV-infected children.
Lipopolysaccharide, bacterial 16S ribosomal DNA (16SrDNA) and soluble CD14 (sCD14) levels were determined in prospectively collected, stored plasma samples from the Pediatric AIDS Clinical Trials Group Protocol P338, a 48-week study initiated in 1997 to compare efficacy of dual nucleosides with a ritonavir-containing regimen. Results of MT were correlated with study data for T cell IA, plasma viral load and CD4 counts in 85 HIV-infected children (ages 2-17 years) designated as virologic responders or virologic failures (VF) at week 44 based on a cutoff of 400 HIV RNA copies/mL.
Levels of plasma lipopolysaccharide, 16SrDNA and sCD14 were increased in comparison with HIV-uninfected controls and did not decrease at week 44 even in virologic responders. T cell IA was correlated with viral load and sCD14 at entry and with 16SrDNA and sCD14 at week 44 in total patients and in the VF group. Changes in 16SrDNA correlated with changes in IA and negatively with changes in CD4 counts. 16SrDNA was correlated with sCD14 but not with lipopolysaccharide.
MT persists after 44 weeks of antiretroviral therapy in VS and VF patients. In VF, 16SrDNA exhibited relationships to monocyte and T cell IA and CD4 counts but not with viral load, suggesting a dominant role for MT in disease pathogenesis in HIV-infected children.
肠道微生物易位(MT)被认为是 HIV 感染中免疫激活(IA)和免疫重建失败的主要原因。本研究调查了 HIV 感染儿童中病毒复制、IA、CD4 计数和 MT 之间的关系。
前瞻性收集了来自儿科艾滋病临床试验组方案 P338 的存储血浆样本,该方案于 1997 年启动,旨在比较双重核苷与含利托那韦方案的疗效。从该方案中选择了 85 名 HIV 感染儿童(年龄 2-17 岁)作为研究对象,根据 400 HIV RNA 拷贝/mL 的截止值,在第 44 周将这些儿童分为病毒学应答者或病毒学失败(VF)。测定这些儿童血浆中脂多糖、细菌 16S 核糖体 DNA(16SrDNA)和可溶性 CD14(sCD14)的水平,并将 MT 结果与 T 细胞 IA、血浆病毒载量和 CD4 计数的研究数据相关联。
与 HIV 未感染者相比,这些儿童血浆中脂多糖、16SrDNA 和 sCD14 的水平升高,即使在病毒学应答者中,这些水平在第 44 周也没有下降。在所有患者和 VF 组中,T 细胞 IA 在进入时与病毒载量和 sCD14 相关,在第 44 周与 16SrDNA 和 sCD14 相关。16SrDNA 的变化与 IA 的变化相关,与 CD4 计数的变化呈负相关。16SrDNA 与 sCD14 相关,但与脂多糖不相关。
在 VS 和 VF 患者接受抗逆转录病毒治疗 44 周后,MT 持续存在。在 VF 中,16SrDNA 与单核细胞和 T 细胞 IA 和 CD4 计数相关,但与病毒载量无关,这表明 MT 在 HIV 感染儿童的疾病发病机制中起主导作用。